Perimeter Medical Imaging AI Inc. reported a 31% sequential revenue increase to $503,000 in the second quarter of 2026, driven entirely by recurring sources including system leases, consumables, and maintenance services. The company’s net loss narrowed to $2.6 million, or $0.02 per share, a 33% improvement from a $3.9 million loss in the same period last year.
Operating expenses declined 28% year-over-year to $3.1 million, while operating cash burn for the first six months of 2026 totaled $5.1 million, down 23% from the prior-year period. Cash and cash equivalents stood at $6.4 million as of June 30, 2026, providing an estimated 12-month runway based on current burn rates and capital raise proceeds. Shares traded 2.7% lower at $0.36, near the lower end of its 52-week range between $0.17 and $0.72.
The company highlighted the commercial launch of its FDA-approved Claire AI-enabled imaging device, which received premarket approval in March 2026. Perimeter has filed for HCPCS reimbursement codes with the Centers for Medicare & Medicaid Services, currently under review. The first two Claire systems were deployed as conversions from existing S-Series customers, marking the technology’s initial commercial use in a hospital setting.
Perimeter maintains an installed base of 22 sites, including both legacy S-Series and new Claire systems. The company’s commercial focus remains concentrated in regions with existing customer presence, including Dallas, Utah, Colorado, and Phoenix. Management emphasized operational discipline, with operating expenses expected to grow modestly for the remainder of 2026, primarily in sales and marketing.
During the earnings call, Chief Executive Officer Adrian Mendes described the period as a pivotal inflection point, citing anticipated rapid growth as Claire deployments expand. Mendes also addressed hospital concerns regarding AI integration, noting that the system operates as a fixed, offline algorithm with no continuous learning or internet connectivity, reducing perceived operational risks.
Analysts from Raymond James and Brookline Capital Markets participated in the call, which was held on August 18, 2026, and published two days later.
